MIDATECH PHARMA
About Us

An international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas.

Midatech is commercialising oncology treatment and supportive care products through its US commercial organisation, Midatech Pharma US (“Midatech US”) (formerly DARA BioSciences, Inc.). In Europe, Midatech is developing a pipeline of product candidates in clinical and pre-clinical development for diseases for which there are currently few or no treatment options available. These diseases include diabetes, rare cancers including brain (glioblastoma), ovarian, liver and pancreatic cancer and neurological/ophthalmologic conditions.

Midatech’s strategy is to expand its US commercial arm as well as develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

All of Midatech’s product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery (‘right place’) and controlled release (‘right time’) of existing drugs.

Midatech’s core platform is a drug conjugate delivery system based on a patented form of gold nanoparticles (GNP) combined with existing drugs for the safe and targeted release of therapeutic payloads at specific organs, cells or sites of disease.

The Group’s second platform is a sustained release technology acquired with Q-Chip that involves the consistent and precise encapsulation of active drug compounds within polymer microspheres enabling their release into the body in a highly controlled manner over a prolonged period of time.

Midatech is collaborating with a number of universities, and specialty and major pharmaceutical companies to develop its platform technologies into a broad number of products in order to achieve a range of potential revenue opportunities within priority therapeutic areas. Collaboration partners include several pharmaceutical and biotechnology companies and the Dana-Faber Cancer Institute (an affiliate of Harvard Medical School). Furthermore, Midatech has a joint venture with MonoSol to develop and commercialise transbuccal delivery, which means the delivery administered through the cheek, of insulin for diabetic patients using insulin conjugated GNPs formulated into dissolvable, oral film strips.

The Group has developed a strong intellectual property base and has a wide IP portfolio of 82 granted patents, 81 applications in process and 30 patent families covering a range of technologies.

Midatech is headquartered near Oxford, UK, with a nanoparticle manufacturing operation in Bilbao, Spain and an R&D facility in Cardiff, UK.

About Us

An international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas.

Midatech is commercialising oncology treatment and supportive care products through its US commercial organisation, Midatech Pharma US (“Midatech US”) (formerly DARA BioSciences, Inc.). In Europe, Midatech is developing a pipeline of product candidates in clinical and pre-clinical development for diseases for which there are currently few or no treatment options available. These diseases include diabetes, rare cancers including brain (glioblastoma), ovarian, liver and pancreatic cancer and neurological/ophthalmologic conditions.

Midatech’s strategy is to expand its US commercial arm as well as develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

All of Midatech’s product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery (‘right place’) and controlled release (‘right time’) of existing drugs.

Midatech’s core platform is a drug conjugate delivery system based on a patented form of gold nanoparticles (GNP) combined with existing drugs for the safe and targeted release of therapeutic payloads at specific organs, cells or sites of disease.

The Group’s second platform is a sustained release technology acquired with Q-Chip that involves the consistent and precise encapsulation of active drug compounds within polymer microspheres enabling their release into the body in a highly controlled manner over a prolonged period of time.

Midatech is collaborating with a number of universities, and specialty and major pharmaceutical companies to develop its platform technologies into a broad number of products in order to achieve a range of potential revenue opportunities within priority therapeutic areas. Collaboration partners include several pharmaceutical and biotechnology companies and the Dana-Faber Cancer Institute (an affiliate of Harvard Medical School). Furthermore, Midatech has a joint venture with MonoSol to develop and commercialise transbuccal delivery, which means the delivery administered through the cheek, of insulin for diabetic patients using insulin conjugated GNPs formulated into dissolvable, oral film strips.

The Group has developed a strong intellectual property base and has a wide IP portfolio of 82 granted patents, 81 applications in process and 30 patent families covering a range of technologies.

Midatech is headquartered near Oxford, UK, with a nanoparticle manufacturing operation in Bilbao, Spain and an R&D facility in Cardiff, UK.

© Copyright 2017 Midatech Pharma PLC